<DOC>
	<DOCNO>NCT03055715</DOCNO>
	<brief_summary>The aim study retrospectively monitor 'gross tumor volume ' ( GTV ) initiation radiotherapy change radiotherapy correlate retrospectively record patient data , well prognostic therapeutic outcome definite radiotherapy locally advance NSCLC stage UICC III .</brief_summary>
	<brief_title>Multicentric Retrospective Prognostic Evaluation Tumor Volume Their Changes Radical Radiotherapy Locally Advanced NSCLC</brief_title>
	<detailed_description>The prognostic relevance 'gross tumor volume ' ( GTV ) radiotherapy advance non-small-cell lung cancer ( NSCLC ) stage III adressed limited number study literature . The review article Dubben et al. , comprise data 1998 , highlight GTV important indicator influence factor therapeutic success radiotherapy , albeit dominant T-stage ( Dubben et al . 1988 ) . In general , increase tumor volume correlate high T-stage ( Martel et al . 1997 ) , congruence neccessarily assume tumor volume T-determinator . Since TNM-classification primarily surgical however , also provide sufficient information prognosis surgical therapy first choice . Available evidence suggest GTV particular begin therapy act statistically significant prognostic indicator regard overall survival / local tumor control ( Martel et al . 1997 ; Bradley et al . 2002 ; Basaki et al . 2006 ; Etiz et al . 2002 ; Werner-Wasik et al . 2001 ; Wer-ner-Wasik et al . 2008 ; Stinchcombe et al . 2006 ; Dehing-Oberije et al . 2008 ; Willner et al . 2002 ; Ball et al . 2013 ) . A direct comparison different study , however , often hamper due large variation measurement time point therapy , well employ definition tumor volume . For example , study include patient whose GTV determine ( neoadjuvant ) chemotherapy . In addition , three study even combine tumor volume primary tumor affect lymph node ( Etiz et al . 2002 ; Werner-Wasik et al . 2008 ; Dehing-Oberije et al . 2008 ) . Furthermore , agreement find literature concerning volume change therapy . Nonetheless , study report volume reduction end therapy , albeit always significant . In study contain 10 patient treated helical Tomotherapy , author observe relative median tumor reduction therapy 1.2 % per day ( 0.6-2.3 % ) ( Kupelian et al . 2005 ) . The response NSCLC radiotherapy without chemotherapy slow ( Woodford et al . 2007 ) tumor reach maximum response minimal volume 5-11 month exposure ( Werner-Wasik et al . 2001 ) . If tumor volume determine early , i.e . directly end therapy , result lead misinterpretation result overestimation tumor volume correspondingly underestimation therapeutic response ( Siker et al . 2006 ) . According Bell et al. , predictive value tumor volume change first 18 month radiotherapy particular importance . During time , significantly increase mortality observe large tumor volume . Incorporation PET/CT context radiaton plan advantageous respect precise traget-volume definition spar risk organ ( Ruysscher et al . 2005 ; Nestle et al . 2006 ; Lavrenkov et al . 2005 ; van Baardwijk et al . 2007 ; Edet-Sanson et al . 2012 ; Ruysscher und Kirsch 2010 ; As-hamalla et al . 2005 ; Bradley et al . 2004 ; van Baardwijk et al . 2006 ; Vanuytsel et al . 2000 ) . The superiority PET compare stand-alone CT also show two meta-analysis ( Gould et al . 2001 ; Gould et al . 2003 ) . The importance 'standardized uptake value ' ( SUV ) metabolic tumor volume ( MTV ) well change parameter radiotherapy repeatedly demonstrate ( Berghmans et al . 2008 , Gillham et al . 2008 ; Zhang et al . 2011 ; van Elmpt et al . 2012 ; Edet-Sanson et al . 2012 ; van Baardwijk et al . 2007 ; Vera et al . 2014 ; Vanuytsel et al . 2000 ; Feifei Na et al . 2014 ; Lopez Guerra et al . 2012 ; Lee et al . 2007 ; Lee et al . 2012 ; Huang et al . 2011 ; Xiang et al . 2012 ) . These study show partly statistically significant correlation tumorale FDG-accumulation , radiotherapy , decrease accumulation radiotherapy , respectively , overall survival . The result , however , suffer large uncertainty regard distinct influence correspond SUV . Other study report significantly weak association SUV survival ( Hoang et al . 2008 ; IKUSHIMA et al . 2010 ; Lopez Guerra et al . 2012 ) . Due dynamic variation SUV MTV radiotherapy , change prognostic validity radiotherapy assume . According van Elmpt others , FDG uptake second ( van Elmpt et al . 2012 ; Zhang et al . 2011 ) fifth week exposure crucial survival ( Edet-Sanson et al . 2012 ) . Work van Baardwijk et al . show increase SUV patient first week therapy , explain radiation-triggered inflammation tumor-biological change due radiotherapy ( van Baardwijk et al . 2007 ) . The result demonstrate appearance tumor necrosis radiotherapy change metabolic tumor situation oxygenation affect SUV parameter crucially ( Hoang et al . 2008 , Huang et al . 2014 ; Huang et al . 2011 ) . In context , tumorhypoxia correspond effect metabolism glucose particularly importance : A hypoxia-simulated upregulation membranic glucose transporter consecutive increase cellular FDG uptage lead false SUV value , call combination SUV MTV prognostic parameter well hypoxia-specific imaging ( FMISO-PET ) ( Ikushima et al . 2010 , Berghmans et al . 2008 ) . Consequently , optimal timevpoint carry PET / radiotherapy well define , especially protracted tumor response completion radiotherapy take account , leave integration additional PET measurement radiotherapy exclusively clinical study . In conclusion , evidence available literature regard prognostic predictive value tumor volume particularly change radiotherapy locally advanced NSCLC conflict inconclusive . Currently available study often include small number patient partly overlap patient cohort . Current data additionally limit due highly heterogeneous GTV detection time point well definition detection methodology tumor volume . Based observation significant tumor volume reduction occur radiotherapy , reevaluation tumor volume radiotherapy could allow adaptation target volume dose escalate tumor area , time , improve protection organ risk . The prognostic predictive significance absolute tumor volume change radiotherapy evaluate multicentrically integration already exist prognostic model multicentrically validate .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm NSCLC ( Adeno / SCC ) Stage UICC III A B PET PETCT within initial radiation planning complete curativeintended radiotherapy ± chemotherapy ( achieve total dose ≥ 60 Gy normofractionated ≥ 50 Gy hypofractionated ) Stereotactic radiotherapy Second malignancy &lt; 5 year diagnosis NSCLC Pleural effusion ipsilateral , extensive atelectasis ipsilateral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>young DEGRO</keyword>
	<keyword>tumor volume</keyword>
	<keyword>lung cancer</keyword>
	<keyword>radiochemotherapy</keyword>
	<keyword>prognostic factor</keyword>
</DOC>